Diagnostic Performance of Carbon Monoxide Testing by Pulse Oximetry in the Emergency Department

Nuria Villalba, Zachary T Osborn, Pamela R Derickson, Chelsea T Manning, Robert R Herrington, David A Kaminsky, and Kalev Freeman

BACKGROUND: Carbon monoxide (CO) exposure causes roughly 40,000 emergency department (ED) visits annually and is commonly misdiagnosed. Whereas the standard method of carboxyhemoglobin (HbCO) measurement utilizes blood gas analysis, a noninvasive, FDA-cleared alternative exists. We evaluated the performance of pulse oximetry (S_{pCO}) for identification of CO exposure in ED patients. **METHODS:** We compared pulse oximetry to blood HbCO levels in a prospective observational study of adult and pediatric subjects recruited from the ED. Nurses screened a convenience sample of patients and referred those with $S_{pCO} \geq 10\%$ to research staff. Researchers also approached individuals who presented with signs and symptoms of CO toxicity. We determined diagnostic performance with a Bland-Altman analysis and calculated sensitivity and specificity for detection of elevated HbCO at thresholds of $\geq 10\%$ and $\geq 15\%$. To optimize the potential sensitivity of S_{pCO} for detection of CO toxicity, research technicians performed 3 S_{pCO} readings within 5 min of the blood draw for laboratory measurement. A positive S_{pCO} test was defined as any $S_{pCO} \geq 10\%$. **RESULTS:** 42,000 patients were screened, 212 were evaluated, and 126 subjects were enrolled. Median HbCO level was 6% (range 1.6–21.9%). Limits of agreement were -10.3% and 8.1% . Of 23 individuals with elevated HbCO $\geq 10\%$, 13 were not suspected based on clinical assessment. Critically elevated HbCO was present in 6 individuals. Based on our a priori threshold of 10% for a positive test, pulse oximetry identified 14 of 23 subjects with HbCO $\geq 10\%$, with a sensitivity of 61% (95% CI 39–80%) and a specificity of 86% (95% CI 78–92%), and 5 of 6 subjects with HbCO $\geq 15\%$, with a sensitivity of 83% (95% CI 36–100%) and a specificity of 81% (95% CI 73–87%). **CONCLUSIONS:** Pulse oximetry underestimated HbCO and produced false negative results (ie, $S_{pCO} < 10\%$ for all three measurements) in 17% of ED subjects with elevated HbCO $\geq 15\%$. Triage screening with pulse oximetry detected cases of elevated HbCO that were not suspected by the clinical provider. *Key words:* hemoglobin; noninvasive monitor; Masimo Radical-7; carbon monoxide; pulse oximetry; point-of-care. [Respir Care 2019;64(11):1351–1357. © 2019 Daedalus Enterprises]

Introduction

Carbon monoxide (CO) exposure causes 40,000 emergency department (ED) visits and 3,000 deaths in the United States each year.^{1,2} Diagnosis of CO toxicity is complicated by non-specific symptoms, and misdiagnosis of CO toxicity is believed to be common.³ The standard method of carboxyhemoglobin (HbCO) measurement is arterial or venous blood

gas analysis.^{3,4} However, a noninvasive point-of-care device (Radical-7 Pulse CO-Oximeter, MX board version 7.5.0.3, Masimo, Irvine, California) has been cleared by the FDA for CO measurement via pulse oximetry (S_{pCO}). The Radical-7 pulse oximeter measures the refraction of 8 wavelengths of light through the nail bed using signal-extraction technology pulse oximetry to noninvasively measure HbCO, methemoglobin (Hbmet), oxyhemoglobin, and pulse rate. The objective of this study was to address the limitations of prior stud-

Drs Villalba, Freeman, and Herrington, as well as Mr Osborn, Ms Derickson, Ms Manning are affiliated with the Department of Surgery, Larner College of Medicine, University of Vermont, Burlington, Vermont. Dr Kaminsky is affiliated with the Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont.

The authors have disclosed a relationship with Masimo.

Correspondence: Kalev Freeman MD PhD, University of Vermont, 89 Beaumont Ave., Given Building, Room E301, Burlington, VT 05405. E-mail: kalev.freeman@uvm.edu.

DOI: 10.4187/respcare.06365

ies and to determine the diagnostic performance of this device in the detection of elevated HbCO under optimal conditions in the ED setting.

SEE THE RELATED EDITORIAL ON PAGE 1450

Despite the promise of multi-wavelength pulse-oximetry technology, controversy exists regarding the agreement of the device with standard laboratory testing.⁵⁻¹⁰ Two studies reported relatively wide limitations of agreement with laboratory measurement but concluded that the device has acceptable bias and correlation for screening purposes.^{5,7} Two additional studies reported satisfactory accuracy and precision for screening subjects in the ED.⁶⁻⁸ Touger et al⁸ found a bias of 1.4% but unacceptably wide limits of agreement (−11.6% to 14.4%), leading them to conclude that S_{pCO} could not be used as a substitute for laboratory testing. Both Roth et al⁹ and Sebbane et al,¹⁰ on the other hand, found similar bias but much narrower limits of agreement, prompting them to recommend the technology for screening patients in the ED. Limitations of prior studies included times between S_{pCO} measurement and blood draws for laboratory analysis of up to 1 h. Furthermore, the performance of diagnostic tests may vary depending on the magnitude of the abnormal value, and previous studies defined elevated CO at relatively low levels (eg, HbCO > 5%). These studies may therefore have failed to adequately assess the utility of pulse oximetry for detecting higher HbCO levels that are more likely to be toxic.⁹ We hypothesized that the sensitivity of pulse oximetry for detecting blood HbCO levels $\geq 10\%$ in patients in the ED setting, under optimal conditions and when performed within a short time interval from the blood test, would be improved relative to previous reports.

We elected to use a multipronged recruitment method to enroll as large a number of true positive (ie, CO-poisoned) patients as possible to determine the performance characteristics of the device for detecting individuals with clinically meaningful CO levels in their blood. We identified patients who presented with either report of a CO exposure or clinical symptoms consistent with CO poisoning. We also screened a convenience sample of non-acute ED patients in triage for elevated S_{pCO} at a 10% threshold. We selected this threshold for elevated HbCO $\geq 10\%$ not because it represents CO toxicity, per se, but because it is above the upper limit for the expected physiological range of smokers, even with recent tobacco use.⁴ Therefore, it represents a clinically meaningful CO elevation in any patient, regardless of the source of CO exposure. To optimize the potential sensitivity of pulse oximetry to detect elevated HbCO, 3 measurements were obtained by trained research technicians. We limited the elapsed time between blood collection and S_{pCO} measurement to < 5 min, thereby

QUICK LOOK

Current knowledge

Despite causing roughly 40,000 emergency department visits annually, misdiagnosis of carbon monoxide (CO) exposure is believed to be common due to its non-specific symptoms. Whereas the standard measurement of carboxyhemoglobin (HbCO) utilizes blood gas analysis, there is a noninvasive, alternative. However, despite noninvasive CO measurement with pulse oximetry, controversy exists regarding the agreement of the device with standard laboratory testing.

What this paper contributes to our knowledge

Despite efforts to optimize the performance of pulse oximetry in this study, we found the limits of agreement between pulse oximetry and laboratory measurement comparable to prior studies in subjects recruited from the emergency department. Pulse oximetry underestimated HbCO overall. Importantly, approximately 17% of subjects with critically elevated blood HbCO levels (ie, HbCO $\geq 15\%$) were missed with the use of pulse oximetry.

eliminating the confounding variable of CO washout. We prospectively compared the experimental measurement of HbCO with S_{pCO} to the criterion standard, which is laboratory measurement of HbCO in the blood sample. We compared concurrent S_{pCO} and HbCO measurements with a Bland-Altman plot and report the limits of agreement. We also report diagnostic performance characteristics for this cohort as sensitivity and specificity of a positive test at the $\geq 10\%$ threshold for the detection of true positive, elevated HbCO at levels of both $\geq 10\%$ and $\geq 15\%$.

Methods

Study Design and Setting

We performed a prospective, observational study to determine the diagnostic performance of the S_{pCO} sensor in the ED setting under optimal experimental conditions. We enrolled a convenience sample of ED patients suspected of having CO toxicity and measured S_{pCO} and HbCO concurrently. Our academic ED at the University of Vermont Medical Center in Burlington, Vermont, sees approximately 60,000 patient visits each year. The study was conducted in accordance with the Standards for the Reporting of Diagnostic Accuracy studies, and we obtained local institutional review board approval.¹¹ This was an investigator-initiated study supported by the manufacturer of the pulse oximeter (Masimo). The authors designed the study, executed the protocol, per-

formed the analysis, and wrote the manuscript. None of the authors received any salary or travel funds or were otherwise supported or employed by the sponsor. The role of the sponsor included funding for the technicians and the administrative costs of the study; loaning of the S_{pCO} sensors and equipment; and data safety monitoring (ie, review of the institutional review board protocol, training of technicians in use of the sensor, and deployment of study monitors to our site to observe enrollment and data collection). The sponsor did not design the study, collect data, analyze results, or write the manuscript.

Selection of Participants

A convenience sample of ED patients was screened for this study. Screening was conducted from June 2011 through March 2014 during times when research staff were available. The screening process was designed to identify patients who were most likely to have elevated CO levels. Potential subjects were referred to research staff by ED clinicians. Referring health care providers were instructed to look for patients with a documented CO exposure or who exhibited signs and symptoms of CO toxicity. These signs and symptoms included headache, dizziness, nausea, generalized weakness, impaired judgment, confusion, or loss of consciousness.⁴ In addition, triage nurses screened patients with pulse oximetry to identify patients with $S_{pCO} \geq 10\%$ and referred these individuals to research staff for potential enrollment. This method of recruitment was utilized to enrich the study population with additional subjects with potentially elevated CO levels on the basis of S_{pCO} , who did not have signs and symptoms of CO toxicity. Both adult and pediatric patients were eligible for enrollment. Research staff evaluated subject eligibility and obtained written informed consent. Exclusion criteria included patients with $Hbmet > 1.6\%$ as determined with pulse oximetry (S_{pHbmet}) because $Hbmet$ interferes with measurement of S_{pCO} . We also excluded patients with acrylic nails, painted fingernails, or fingernail deformities to avoid interference with S_{pCO} measurement.

Interventions

Research staff were trained by the manufacturer and investigators in proper use of the device. Research nurses were also trained to measure S_{pCO} as part of routine triage of ambulatory patients, when time and staffing permitted this assessment. A representative of the manufacturer visited the ED on a quarterly basis to monitor device use and re-train research personnel.

HbCO Measurements

Upon enrollment of a subject, venous blood was drawn and measurement of HbCO was performed by an accred-

ited, in-hospital laboratory using a Sysmex XN9000 hematology analyzer (Sysmex America, Lincolnshire, Illinois). This blood HbCO measurement is considered the criterion standard measure. The laboratory was blind to S_{pCO} levels, and research staff were blind to HbCO results at the time of S_{pCO} measurement. Trained research staff performed S_{pCO} measurement as close to the time of blood draw as possible, from the contralateral arm, and never during tourniquet or blood pressure cuff use. For S_{pCO} measurements, a Rainbow R 1 25 adult adhesive sensor connected to a Radical-7 Pulse CO-Oximeter was placed on the middle finger of the non-dominant hand and covered with an opaque probe cover to eliminate interference from ambient light. The manufacturer recommends 3 S_{pCO} readings to improve accuracy in cases of unexpectedly high S_{pCO} (Radical-7 Signal Extraction Pulse CO-Oximeter Operator's Manual, pp. 6–1, Available at http://www.infiniti.no/upload/Bruksanvisningar/Masimo/MAS_UM_EN_Radical-7%20Color%20Display%20Operators%20Manual.pdf). We performed 3 readings in all cases for consistency, regardless of the S_{pCO} level. We only included measurements taken within 5 min before or after the blood draw for analysis. Subject demographic data were collected from the electronic medical record. Study data were collected and managed using REDCap (Research Electronic Data Capture), a secure, web-based application designed to support data capture for research studies.¹²

Outcomes

To determine performance characteristics across the range of HbCO values, we calculated the average of the 3 S_{pCO} values for each individual subject and compared this to the criterion standard of the blood HbCO with a Bland-Altman analysis. For sensitivity and specificity calculations, we defined a positive pulse-oximeter signal as any of 3 S_{pCO} readings $\geq 10\%$. While some trials have utilized different thresholds for smokers and non-smokers, we used the criterion standard of elevated HbCO as blood HbCO $\geq 10\%$ for all subjects because this is outside of the expected physiological range for smokers.⁴ As a secondary analysis, we also evaluated the sensitivity and specificity of the pulse oximeter to detect the outcome of critically elevated HbCO, defined as levels of blood HbCO $\geq 15\%$. This threshold was based on a study in which 10 healthy controls exhibited no unpleasant symptoms or significant changes in vital signs with $\leq 15\%$ HbCO.¹³

Statistical Analysis

Demographic data were summarized with proportions and with medians and interquartile ranges. We plotted mean versus difference and calculated limits of agreement between the measurements as described by Bland and

Fig. 1. Flow chart.

Altman, showing the mean of the differences between methods ± 1.96 SD above and below the mean.^{14,15} Other measures, including repeatability and confidence intervals for bias and limits of agreement, are reported as recommended by Chhapola et al¹⁶ We determined the diagnostic performance for detection of elevated and critically elevated HbCO according to our a priori outcome criteria. Sensitivity and specificity were calculated with the 95% CIs for the noninvasive hemoglobin measurement (S_{pCO}) to detect the criterion laboratory measurement (HbCO) at levels of $\geq 10\%$ and $\geq 15\%$. Statistical analyses were performed with Microsoft Excel (Microsoft, Redmond, Washington), and graphs were produced with GraphPad Prism 7 (GraphPad Software, La Jolla, California).

Results

Characteristics of Study Subjects

Of approximately 42,000 patients screened by clinical staff during those times when research staff were present, 212 patients were identified by either clinical signs and symptoms or S_{pCO} as potential subjects likely to have elevated HbCO (Fig. 1). Of these, 207 provided informed

Table 1. Subject Characteristics

	Included Subjects	Excluded Subjects
Age, y	36 (27–52)	38 (28–54)
Male	69 (54.8)	25 (34.7)
Caucasian	119 (95.2)	67 (93.1)
Temperature $> 38^{\circ}\text{C}$	4 (3%)	0 (0%)
Heart rate > 100 beats/min	13 (10%)	4 (5%)
HbCO%	6.0 (4.2–9.2)	4.9 (4.1–7.2)
$S_{pCO}\%$	5.3 (2.9–8.0)	4.1 (1.9–7.5)
$S_{pHbmet}\%$	0.4 (0.7–1.1)	1 (0.7–1.5)
Suspicious symptoms (eg, headache, nausea, dizziness, generalized weakness, impaired judgement, confusion, exposure to fire)	72 (57%)	41 (58%)
Treated with oxygen therapy	15 (13.6)	6 (11)
Time between blood sample and cooxymetry reading, min	1 (0–3)	8.5 (3–20)

N = 198 subjects (126 included subjects; 72 excluded subjects).

Data are shown as *n* (%) or median (interquartile range).

consent. Twelve were excluded for acrylic or polished nails, 13 for $S_{pHbmet} > 1.6$, and 47 because > 5 min had elapsed between measurements. Nine subjects were missing either HbCO or S_{pCO} data and were not analyzed. Thus, a total of 126 subjects were included in the analysis. Subjects ranged in age from 15 y to 89 y and reported a wide variety of chief complaints, such as fever, chest or abdominal pain, or trauma. Included subjects and excluded patients had similar demographic and clinical characteristics except for sex: 54.8% of included subjects and 34.7% of excluded patients were male (Table 1).

Statistical Analysis

Of the 126 subjects analyzed, the range of HbCO levels was 1.6–21.9% with a median of 6.0% (interquartile range 4.2–9.2%). The S_{pCO} readings for these subjects ranged from 0 to 23.6% with a median of 5.3% (interquartile range 2.9–8.0%). For quantitative comparison of S_{pCO} to HbCO, we used the average of the 3 S_{pCO} readings for each individual. The scatter plot of HbCO versus S_{pCO} showed a weak positive relationship ($r = 0.292$, $P < .001$) (Fig. 2). The mean difference plot (Fig. 3) showed no evidence of heteroscedasticity (differences in magnitude proportional to the size of the measurements). S_{pCO} was most often an underestimation of HbCO level, as shown by the calculated bias of -1.1% for the mean difference ($\text{HbCO} - S_{pCO}$). The limits of agreement from Bland-Altman analysis were -10.3% to 8.1% (Table 2).

We determined the sensitivity and specificity of positive S_{pCO} (defined a priori as any of 3 measurements $\geq 10\%$) for detection of elevated HbCO. On the basis of the diag-

Fig. 2. Scatterplot of laboratory HbCO vs pulse oximetry S_{pCO} readings.

Fig. 3. Bland-Altman plot of difference against mean for HbCO and S_{pCO} readings.

Table 2. Bland-Altman Bias and Limits of Agreement

	Estimate (95% CI)
Bias (mean difference)	-1.1% (-1.9% to 0.3%)
Limit of agreement (upper)	8.1% (7.4% to 8.8%)
Limit of agreement (lower)	-10.3% (-11.0% to -9.6%)

nostic criterion of elevated HbCO $\geq 10\%$, our cohort of 126 individuals consisted of 23 true positives and 103 true negatives (Table 3). S_{pCO} was positive in 14 of the 23 true positive subjects, with 9 false negatives (sensitivity 61% [95% CI 39–80%]); S_{pCO} was negative in 89 of 103 true negative subjects, with 14 false positives (specificity 86% [95% CI 78–92%]). Of these 23 individuals with blood levels of HbCO $\geq 10\%$, 10 were suspected by the treating clinicians to have CO toxicity (4 had a known exposure and 6 had symptoms indicating possible CO toxicity). On the other hand, 13 individuals had neither symptoms nor a known exposure and might therefore be considered “occult” CO toxicity. We also determined the sensitivity and specificity for detection of critically elevated HbCO de-

Table 3. Sensitivity and Specificity of Pulse Oximeter in Detection of Elevated Blood HbCO at the Criterion Standards

Blood HbCO $\geq 10\%$ *			
Cooximeter	+	–	Total
+	14	14	28
–	9	89	98
Total	23	103	126
Blood HbCO $\geq 15\%$ †			
Cooximeter	+	–	Total
+	5	23	28
–	1	97	98
Total	6	120	126

* Sensitivity = 61% (39%–80%); specificity = 86% (78–92%).

† Sensitivity = 83% (36–100%); specificity = 81% (73–87%).

fined as levels $\geq 15\%$. At this threshold, the sensitivity of S_{pCO} was 83% (95% CI 36–100%) and the specificity was 81% (73–87%) (Table 3).

We performed a pre-planned sensitivity analysis to determine the extent of bias that might have been introduced by dropping subjects in whom S_{pCO} could not be obtained or who were excluded for other reasons. Thus, we compared the demographic characteristics and HbCO levels in the 72 subjects who were excluded to the 126 who were analyzed (Table 1). The HbCO in the excluded subjects averaged 5.4% (SD 5.2%), which was not significantly different from those subjects who were included. Of note, one dropped subject with a known CO exposure and critically elevated HbCO level of 20.5% was missed by the device, which incorrectly reported elevated S_{pHbmet} and normal S_{pCO} . Another subject with a HbCO level of 15.3% also escaped detection, likely due to acrylic nail polish. Elevated S_{pHbmet} and nail polish were a priori exclusion criteria, so these individuals were not included in the primary analysis.

We performed 3 readings in all cases, regardless of S_{pCO} level. However, the manufacturer’s operations manual recommends taking the average of 3 readings to improve accuracy only in cases of unexpectedly high S_{pCO} . An S_{pCO} reading was considered “unexpectedly high” if the subject was not previously suspected of exposure to CO. In normal clinical use, it is therefore more likely that only a single measurement would be performed. We attempted to simulate this by re-analyzing the sensitivity and specificity for the first reading only. In a mean difference analysis of first measurements only, bias was slightly smaller (–0.8%) and limits of agreement widened slightly to –10.4% to 8.7%. Because 2 subjects with blood levels $\geq 10\%$ were only identified on the second or third S_{pCO} reading, use of the first reading only produced a lower sensitivity of 52% (31–73%) with a specificity of 88% (81–94%).

Discussion

Venous blood oximetry is accurate and precise, but phlebotomy is invasive and blood analysis requires time and a credentialed laboratory. Pulse oximetry offers a point-of-care alternative to rapidly screen for elevated HbCO without drawing blood. The diagnostic performance of pulse oximetry for the detection of elevated HbCO in the ED is controversial. We identified 3 studies that evaluated pulse oximetry technology by comparing S_{pCO} to the accepted standard of laboratory measurement and which met Standards for Reporting of Diagnostic Accuracy and reported agreement using Bland and Altman's approach.⁸⁻¹¹ Touger et al⁸ studied 120 ED subjects with a suspected diagnosis of CO toxicity and reported limits of agreement from a Bland-Altman analysis of -11.6% and 14.4% HbCO. The authors defined the a priori threshold as agreement $< 5\%$ HbCO and concluded that S_{pCO} measurement may not be used interchangeably with laboratory measurement. Later, Roth et al⁹ studied a larger sample of 1,500 unselected subjects in the ED and reported slightly better limits of agreement of -3.6 to 9.5 HbCO. They concluded that S_{pCO} measured HbCO with acceptable bias and precision. However, they identified only 17 subjects with CO poisoning, which was defined clinically and included non-smokers with levels of HbCO that were $< 10\%$. In addition, their S_{pCO} measurements were made within 60 min of the HbCO measurement. Sebbane et al¹⁰ reported on 93 subjects with suspected CO toxicity, including 26 with CO poisoning (defined as blood HbCO $> 5\%$ for non-smokers and $> 10\%$ for smokers), and found limits of agreement of -6.7% and 6.3% . Measurements were made within a mean of 19 min (95% CI 10–29 min).

We attempted to improve on previous studies in several ways. We utilized a dedicated research team to recruit ED subjects who were suspected of having CO toxicity. We identified clinically meaningful levels of HbCO $\geq 10\%$ for elevated and $\geq 15\%$ for critically elevated for all CO exposures, including tobacco and other causes. We excluded measurements made > 5 min apart to reduce the effect of CO washout between measurements. We worked with representatives from the manufacturer to ensure ideal training, technique, and equipment function. We also conducted 3 S_{pCO} measurements in each case, using the average of the 3 for Bland-Altman analysis, and we used any reading $> 10\%$ as our definition of a positive test for sensitivity and specificity analysis. These efforts produced a rigorous set of experimental data, including subjects with a range of CO levels, but the performance characteristics of pulse oximetry were not better than in previous studies.

Our sensitivity analysis resulted in only slight changes in the main results. Re-analysis using only 1 S_{pCO} reading yielded slightly lower sensitivity and slightly higher specificity. Bias slightly decreased in magnitude, but at the

cost of wider limits of agreement. Including all excluded subjects (eg, artificial nails, nail polish, $S_{pHbmet} > 1.6\%$, and > 5 min elapsed between methods) again revealed a slightly smaller bias but wider limits of agreement that did not appear substantially different from the restricted dataset. One subject who was excluded due to elevated S_{pHbmet} and had a HbCO level of 20.5% warrants discussion. This individual was symptomatic, and blood analysis confirmed elevated HbCO without Hbmet elevation, but the device missed this diagnosis, reporting S_{pHbmet} elevation with normal S_{pCO} on multiple measurements. Thus, clinicians should be aware of the potential for oximetry to incorrectly suggest methemoglobinemia in some CO toxicity cases.

The relative infrequency of elevated HbCO levels among the large number of potentially eligible subjects is a limitation. It is difficult to identify subjects while they still have high HbCO levels, in part because the half-life of carbon monoxide, even with room air, is < 3 h. It often takes minutes to hours to capture and consent ED patients with CO toxicity, and by this time their blood levels may start to decline. Furthermore, although S_{pCO} measurements occurred within 5 min of the blood draw, the elapsed time between the draw and the measurement of HbCO in the blood sample by the hospital's accredited laboratory was not recorded. It is possible that HbCO levels within the sample could have changed during this time period.

Although we conducted 3 S_{pCO} measurements for all subjects, it is unlikely that this would occur in most clinical applications. Our sensitivity analysis found that when we used only the first of 3 S_{pCO} measurements, sensitivity dropped to only 52% (95% CI 31–73%). Relatively small numbers of true positives result in wide confidence intervals for sensitivity and specificity of the device. We therefore intentionally used a strategy to enrich our sample for subjects most likely to include true positives, enrolling specifically those subjects who were suspected to have CO toxicity due to report of an exposure, clinical symptoms, or S_{pCO} screening levels. This sampling strategy itself has limitations. Among these is the possibility that the subjects recruited from triage may be intrinsically different than those recruited via clinician referral.

We used a threshold of HbCO $\geq 10\%$ as the upper limit of normal cutoff for screening for elevated HbCO in all subjects with or without smoking history. In clinical practice, HbCO levels $> 4\%$ in non-smokers and $> 10\%$ in smokers can be considered outside the normal physiological range.⁴ Two previous studies, one with a cutoff of 6.6% HbCO for all subjects and the other with cutoffs of 9% for smokers and 6% for non-smokers, reported the best combination of sensitivity and specificity for use as a screening tool for CO poisoning.^{9,10} We settled on a single-criterion standard for elevated HbCO of blood HbCO $\geq 10\%$ because it falls outside of the physiological range for both smokers and non-smokers and because the source

of CO exposure is important in clinical management but irrelevant to the performance of the assay.⁴ Regardless of the threshold that may be applied, the Bland-Altman analysis provides an estimate of performance characteristics and allows comparison between the different studies, independent of thresholds used for the criterion diagnosis. We did not define a priori accepted Bland-Altman limits of agreements, however our limits did fall outside the previously defined < 5% HbCO a priori limits established by Touger et al.⁸

It should be noted that our study was not designed to test the utility of the device for triage screening of all patients presenting to the ED triage. To assess utility for triage screening, blood testing would need to be performed on all of the 42,000 potentially eligible patients who were screened. This was beyond the scope of our study. That being said, our results offer conflicting clues as to the efficacy of the device in such an application. On the one hand, pulse oximetry returned false negatives for 39% of subjects with HbCO $\geq$ 10%. This figure fell to 17% of subjects above the critically elevated threshold of HbCO $\geq$ 15%. On the other hand, we did identify 13 individuals with elevated CO levels without symptoms or a known exposure. This suggests ED triage screening with pulse oximetry has utility in identification of some individuals with occult CO poisoning.

Conclusion

Despite efforts to optimize the performance of pulse oximetry in this study, we found the limits of agreement between pulse oximetry and laboratory measurement of -10.3% and 8.1% , which were comparable to prior studies in subjects recruited from the ED. S_{pCO} slightly underestimated HbCO overall with a bias of -1.1% .

Although our study was not specifically designed to evaluate the role of pulse oximetry in triage, we noted that triage screening of ED patients with pulse oximetry identified CO exposure in approximately 0.05% of patients, about half of whom might have been missed by clinical assessment alone. Future studies that include blood measurements in all eligible subjects are needed to determine the utility of this device as a screening tool. The sensitivity and specificity results we provide for detection of HbCO at clinically important thresholds should aid clinicians seeking to use S_{pCO} for medical decision-making in the ED setting.

REFERENCES

1. Hampson NB. Emergency department visits for carbon monoxide poisoning in the Pacific Northwest. *J Emerg Med* 1998;16(5):695-698.
2. Centers for Disease Control and Prevention (CDC). Carbon monoxide-related deaths: United States, 1999-2004. *MMWR Morb Mortal Wkly Rep* 2007;56(50):1309-1312.
3. Wolf SJ, Lavonas EJ, Sloan EP, Jagoda AS. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. *Ann Emerg Med* 2008;51(2):138-152.
4. Hampson NB, Piantadosi CA, Thom SR, Weaver LK. Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning. *Am J Respir Crit Care Med* 2012;186(11):1095-1101.
5. Suner S, Partridge R, Sucov A, Valente J, Chee K, Hughes A, et al. Non-invasive pulse CO-oximetry screening in the emergency department identifies occult carbon monoxide toxicity. *J Emerg Med* 2008;34(4):441-450.
6. O'Malley GF. Non-invasive carbon monoxide measurement is not accurate. *Ann Emerg Med* 2006;48(4):477-478.
7. Piatkowski A, Ulrich D, Grieb G, Pallua N. A new tool for the early diagnosis of carbon monoxide intoxication. *Inhal Toxicol* 2009;21(13):1144-1147.
8. Touger M, Birnbaum A, Wang J, Chou K, Pearson D, Bijur P. Performance of the RAD-57 pulse co-oximeter compared with standard laboratory carboxyhemoglobin measurement. *Ann Emerg Med* 2010;56(4):382-388.
9. Roth D, Herkner H, Schreiber W, Hubmann N, Gamper G, Laggner AN, et al. Accuracy of noninvasive multiwave pulse oximetry compared with carboxyhemoglobin from blood gas analysis in unselected emergency department patients. *Ann Emerg Med* 2011;58(1):74-79.
10. Sebbane M, Claret PG, Mercier G, Lefebvre S, Thery R, Dumont R, et al. Emergency department management of suspected carbon monoxide poisoning: role of pulse CO-oximetry. *Respir Care* 2013;58(10):1614-1620.
11. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *Fam Pract* 2004;21(1):4-10.
12. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42(2):377-381.
13. Barker SJ, Curry J, Redford D, Morgan S. Measurement of carboxyhemoglobin and methemoglobin by pulse oximetry: a human volunteer study. *Anesthesiology* 2006;105(5):892-897.
14. Bland JM, Altman DG. Measuring agreement in method comparison studies. *Stat Methods Med Res* 1999;8(2):135-160.
15. Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. *J Biopharm Stat* 2007;17(4):571-582.
16. Chhapola V, Kanwal SK, Brar R. Reporting standards for Bland-Altman agreement analysis in laboratory research: a cross-sectional survey of current practice. *Ann Clin Biochem* 2015;52(Pt 3):382-386.

This article is approved for Continuing Respiratory Care Education credit. For information and to obtain your CRCE (free to AARC members) visit www.rcjournal.com